Literature DB >> 2901959

The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase.

H G Aldenhövel1.   

Abstract

In 110 patients receiving long-term anti-convulsant monotherapy with diphenylhydantoin (DPH) and carbamazepine (CBZ) the serum activities of gamma-glutamyltransferase (gamma-GT), aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase (AP) were examined retrospectively. Elevated serum levels of gamma-GT and AP were seen in 91% and 39% of patients receiving DPH therapy compared to 64% and 14% of those receiving CBZ treatment. With all enzymes evaluated increases were more frequent and higher with DPH treatment than with CBZ. Frequency and extent of increased activity of gamma-GT were highly related to daily dosage in both preparations. The proportion of pathological enzyme levels was associated with age in DPH and CBZ therapies but not found to be significant. Sex differences in the frequency of increased enzyme activities could not be demonstrated. The results are discussed in the context of induction of the cytochrome P-450 system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901959     DOI: 10.1007/bf00450552

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  25 in total

1.  [Clinical pharmacology of carbamazepine--a comparison with phenytoin].

Authors:  L Bertilsson; K Ekbom; F Sjöqvist; T Tomson
Journal:  Lakartidningen       Date:  1985-04-10

2.  [Hepatic drug interactions].

Authors:  R Gugler
Journal:  Fortschr Med       Date:  1985-11-07

3.  Granulomatous hepatitis secondary to carbamazepine.

Authors:  M Levy; M W Goodman; B J Van Dyne; H W Sumner
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

4.  Phenytoin hepatotoxicity: a case report and review.

Authors:  W A Parker; C A Shearer
Journal:  Neurology       Date:  1979-02       Impact factor: 9.910

5.  Serum low-density lipoprotein and high-density lipoprotein cholesterol, and liver size in subjects on drugs inducing hepatic microsomal enzymes.

Authors:  P V Luoma; E A Sotaniemi; R O Pelkonen; H I Pirttiaho
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants.

Authors:  H I Pirttiaho; E A Sotaniemi; R O Pelkonen; U Pitkänen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Phenytoin monotherapy for epilepsy: a long-term prospective study, assisted by serum level monitoring, in previously untreated patients.

Authors:  E H Reynolds; S D Shorvon; A W Galbraith; D Chadwick; C I Dellaportas; L Vydelingum
Journal:  Epilepsia       Date:  1981-08       Impact factor: 5.864

8.  Fatal carbamazepine-associated hepatitis. Report of two cases.

Authors:  G Hopen; I Nesthus; O D Laerum
Journal:  Acta Med Scand       Date:  1981

9.  Hepatic injury associated with diphenylhydantoin therapy. A clinicopathologic study of 20 cases.

Authors:  F G Mullick; K G Ishak
Journal:  Am J Clin Pathol       Date:  1980-10       Impact factor: 2.493

10.  The effects of phenobarbital and diphenylhydantoin on liver function and morphology.

Authors:  H W Aiges; F Daum; M Olson; E Kahn; S Teichberg
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

View more
  3 in total

1.  Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy.

Authors:  A B Okesina; D Donaldson; P T Lascelles
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

2.  Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.

Authors:  Yu-Lung Tseng; Chi-Ren Huang; Chih-Hsiang Lin; Yan-Ting Lu; Cheng-Hsien Lu; Nai-Ching Chen; Chiung-Chih Chang; Wen-Neng Chang; Yao-Chung Chuang
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889

3.  Fibrinogen storage disease in a Chinese boy with de novo fibrinogen Aguadilla mutation: Incomplete response to carbamazepine and ursodeoxycholic acid.

Authors:  Mei-Hong Zhang; A S Knisely; Neng-Li Wang; Jing-Yu Gong; Jian-She Wang
Journal:  BMC Gastroenterol       Date:  2016-08-12       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.